Topic

Biotech stocks

Publicly traded biotechnology and life-science tools companies and the market forces that move their share prices.

Current clusters

science2 publishers

Jury awards Nektar less than a tenth of the $1 billion it sought from Lilly

Jurors found Eli Lilly broke good faith in ending its rezpeg deal with Nektar Therapeutics and awarded Nektar $90 million plus interest. Nektar's shares still fell about 4% on Friday as investors set the award against a far larger ask.

Publishers:genengnews.comstatnews.com

Reality

Evidence62
Adoption: Insufficient
Hype gap0
Incentives50
Confidence64

science3 publishers

Phase III for a bespoke mRNA cancer therapy repriced the sequencing vendors, not just Moderna

Merck and Moderna put out no efficacy figures. Illumina still rose 16% and PacBio 18%, because an approved per-patient therapy implies a sequencing run per patient.

Publishers:genengnews.comsciencenews.orgstatnews.com

Perspective Coverage

3 publishers

Builder: Builder 27%
Operator: Operator 32%
Investor: Investor 41%

Reality

Evidence45
Adoption: Insufficient
Hype gap+40
Incentives55
Confidence55